| 前收盘价格 | 31.32 |
| 收盘价格 | 31.61 |
| 成交量 | 1,787,876 |
| 平均成交量 (3个月) | 1,106,617 |
| 市值 | 2,083,595,648 |
| 价格/销量 (P/S) | 20.41 |
| 股市价格/股市净资产 (P/B) | 1.99 |
| 52周波幅 | |
| 利润日期 | 5 Nov 2026 |
| 营业毛利率 | 1,798.26% |
| 营业利益率 (TTM) | -1,221.97% |
| 稀释每股收益 (EPS TTM) | 11.54 |
| 季度收入增长率 (YOY) | 6.60% |
| 总债务/股东权益 (D/E MRQ) | 3.61% |
| 流动比率 (MRQ) | 18.50 |
| 营业现金流 (OCF TTM) | -401.46 M |
| 杠杆自由现金流 (LFCF TTM) | -237.66 M |
| 资产报酬率 (ROA TTM) | -22.88% |
| 股东权益报酬率 (ROE TTM) | 60.26% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Agios Pharmaceuticals, Inc. | 混合的 | 看跌 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -1.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -0.5 |
| 相对估值 | NA |
| 财务健康 | 5.0 |
| AI Insight | NA |
| 平均 | 0.29 |
|
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 1.65% |
| 机构持股比例 | 101.39% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Lynx1 Capital Management Lp | 30 Jun 2026 | 3,408,937 |
| Erste Asset Management Gmbh | 30 Jun 2026 | 2,154,900 |
| Nomura Investment Management Business Trust | 30 Jun 2026 | 2,110,809 |
| Assenagon Asset Management S.A. | 30 Sep 2026 | 1,886,412 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合